Proteu00ecna hu00ecbrida, sequence of recombinant nucleic acids, vectors / plasmu00ecdeos, pharmaceutical formulations and / or veterinary and its uses in the control of tumors induced by vu00ecrus human papilloma and / or infectious diseases or degenerative

摘要

Proteu00ecna hu00ecbrida, sequence of recombinant nucleic acids, vectors / plasmu00ecdeos, pharmaceutical formulations and / or veterinary and its uses in the control of tumors induced by vu00ecrus human papilloma and / or infectious diseases or degenerative.The present invention provides a hybrid protein, not natural, formed by the fusion of the oncoproteu00ecna E7 gene of human papilloma vu00ecrus type 16 (HPV-16) with a modified form of the glicoproteina D (GD) of herpes simplex virus type 1 (HSV-1)Deleted in its peptide signal and in the region C - terminal that includes the sequence involved in the binding to the cytoplasmic membrane (corresponding to the amino acid sequence of 320 344), sequence of recombinant nucleic acids (SEQ. ID. No. 1 and SEQ. ID. in the.2) encoding recombinant protein, recombinant plasmid containing the sequence vectors / and / or veterinary and pharmaceutical formulations containing the hybrid protein and / or the recombinant sequence that encode, preferably in the form of vaccines.In addition, this patent application is for the use of genetic construct, as an adjunct to the other vaccine antigens and / or as an active ingredient in the preparation of pharmaceutical formulation and / or veterinary indicated for the control of tumors induced by the human papilloma virus And infections with herpes viruses.